Participated · Series C · Apr 2026

True Footage builds a full-stack residential valuation solution combining proprietary software, data science, and in-house appraisal services, anchored by its flagship platform TrueTracts. The platform provides appraisers with market analysis, time and feature adjustments, trend insights, and AI-driven analytics designed to improve consistency, compliance, and efficiency. The company has processed millions of appraisals and employs hundreds of appraisers across 33 states, serving roughly 300 mortgage lenders including seven of the top ten U.S. lenders. Founded in 2021 and based in Austin, Texas, True Footage emphasizes integrating advanced analytics directly into the appraisal workflow rather than selling standalone tools. The company plans to expand its valuation services across major consumer brands, government entities, and the broader mortgage ecosystem while deepening integrations with other real estate technology platforms. Financially, True Footage has raised more than $105 million in total, including the recently announced $40 million Series C.

Participated · Seed · Sep 2022

Prolific Machines develops a photomolecular biology platform that leverages optogenetics, proprietary hardware, and AI to deliver precise, light-driven control of cellular processes across cell types. The company positions its technology for biomanufacturing applications ranging from nutritional proteins to lifesaving biologics and novel biosolutions. With support from the Bill & Melinda Gates Foundation, Prolific will apply its platform to demonstrate lower-cost production of monoclonal antibodies (mAbs) aimed at preventing infectious diseases such as malaria, HIV, and RSV in low- and middle-income countries. The effort targets reduced cost per dose and improved product quality to expand access in regions where mAbs are currently unaffordable. Prolific says successful methods could be readily applied to other unmet medical needs and enable broad implementation in vulnerable populations. The company is based in Emeryville, Calif., and is supported by investors including The Ki Tua Fund (Fonterra’s corporate venture arm), Breakthrough Energy Ventures, Mayfield, SOSV, In-Q-Tel, and others. The Gates Foundation grant amount was not disclosed in the announcement. Prolific Machines builds a photomolecular/optogenetic platform that leverages light-sensitive proteins and genetic methods to manipulate cellular activity. The company targets biomanufacturing applications across pharmaceuticals and cultivated meat to improve efficiency, cost-effectiveness, and product quality. Its approach uses precise light signals to steer cellular behavior, emphasizing precision engineering and scalability. Environmental sustainability is cited as a core goal of their platform and processes. The company announced a $55 million Series B1 round led by the Ki Tua Fund, reflecting investor backing for commercialization. The articles reference both California and Kirkland, Washington as locations and mention founding years of 2016 and 2020 in different places within the coverage. Prolific Machines is inventing scalable biomanufacturing technology to grow and differentiate stem cells at dramatically lower cost relative to conventional methods, with an initial focus on cultured meat. Unlike other cultured meat companies, Prolific prioritizes inventing the scalable manufacturing process first and aims to enable an assembly line for biology that could be made available to other meat companies. The company says its approach can grow and control cells without the need for recombinant proteins, reducing one of the most expensive inputs in cell production. The founding team includes CEO and co-founder Dr. Deniz Kent, co-founder Dr. Max Huisman, and machine‑learning engineer Declan Jones; Kent conceived the idea after witnessing the Syrian refugee crisis in Antioch, Turkey. Prolific is building a 25,000 square foot HQ in Emeryville and is ramping up hiring to expand its assembly line programs across fish, poultry, and beef. Financially, the company announced massively oversubscribed Seed and Series A financings totaling $42M, and was incubated and pre-seeded by IndieBio (SOSV).

Participated · Series B · Jul 2022

CAMP4’s core product is its RNA Actuating Platform (RAP™), which maps regulatory RNAs (regRNAs) associated with protein-coding genes and enables programmable antisense oligonucleotides (ASOs) to upregulate gene expression. The company focuses on developing ASO therapeutics to treat genetic diseases where tunable increases in gene output can be therapeutic, with an initial emphasis on central nervous system and liver indications. CAMP4 plans to enter the clinic with its lead candidate for Dravet syndrome by mid-2023 and to advance a urea cycle disorder program into the clinic. The company intends to continue building an expansive pipeline of RNA actuators and believes the platform can address a broad range of haploinsufficient and other genetic indications across tissues. Financially, CAMP4 closed a $100 million Series B to support clinical development and platform expansion. The financing was led by Enavate Sciences (a Patient Square Capital portfolio company) and included participation from a national managed-care organization, Gaingels, and existing investors such as 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz and The Kraft Group.

Participated · Series B · Jul 2022

CAMP4 harnesses regulatory RNAs (regRNAs) and a proprietary RNA Actuating Platform (RAP™) to map regRNAs controlling protein-coding genes and program antisense oligonucleotides (ASOs) to increase gene expression. Its approach targets the “dark side” of the genome to upregulate gene output, aiming to treat diseases where increased protein expression is therapeutic, with a focus on haploinsufficient disorders. The company is initially concentrating on central nervous system and liver indications. CAMP4 expects to enter the clinic with a lead candidate for Dravet syndrome by mid-2023 and plans to progress a urea cycle disorder program into the clinic. The platform is positioned to build an expansive pipeline of RNA actuators across multiple tissues. The company announced a $100 million Series B to accelerate advancement of its lead programs and expansion of its regRNA Actuating Platform. CAMP4 combines a proprietary RNA Actuating Platform (RAP) with oligonucleotide technology to create programmable therapeutics called RNA Actuators that tunably increase gene expression. The company focuses on targeting cis-acting regulatory RNAs (regRNAs) to adjust transcriptional output for diseases where modest increases in gene expression are therapeutic. CAMP4 has used next-generation sequencing and AI to map transcriptional machinery across tissues including liver, muscle, brain and heart to identify gene-specific regulatory RNA targets. Its current pipeline prioritizes indications where oligonucleotides have proven safe and effective, notably CNS and liver diseases, with potential expansion to muscle and heart. CAMP4 expects to file an Investigational New Drug application by late next year and is advancing multiple preclinical RNA therapies toward human testing. The company raised $45 million to expand its platform and accelerate those programs; it was founded in 2016. Camp4 Therapeutics has developed a Gene Circuitry Platform that amplifies the value of cellular and genetic insights to understand how genes are controlled by signaling pathways in specific disease states. The platform generates proprietary 4D maps to identify de-risked druggable targets, produce actionable insights and improve therapeutic predictability. The company says this approach could potentially address hundreds of diseases and benefit millions of patients globally. Camp4 was co-founded in 2016 by Dr. Richard Young and Dr. Leonard Zon and is led by CEO Josh Mandel-Brehm. The company is based in Cambridge, MA. It raised financing to expand its development efforts.

Participated · Series C · Jun 2022

Evolved By Nature develops a proprietary library of Activated Silk™ molecules derived from natural silk protein to protect, repair, and enhance the barrier function of surfaces. Its Activated Silk biotechnology is positioned to enable next-generation products across textiles, personal care, aesthetic and medical treatments, therapeutics and more. The company reports commercial adoption of its biodegradable, high-performance finishes by fashion brands including Anya Hindmarch, nylon mills such as Alpine Creations and Apex Holdings, and leather tanneries including Richard Hoffmans GmbH & Co. KG, Cyclica Srl and Curtidos Bengala. The financing will support commercialization of the Activated Silk technology platform and the company’s goal of reducing dependence on synthetics and fossil-fuel derivatives. The round coincides with the launch of a full-scale manufacturing facility in Walpole, Massachusetts, which will ramp production to 900 metric tons of Activated Silk™ per year. Evolved By Nature was founded in 2013 by Dr. Greg Altman (CEO) and Dr. Rebecca Lacouture (President, COO) and is based in Boston, Massachusetts.